An allogeneic NK cell line engineered to express chimeric antigen receptors

References

• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306 - 15; http://dx.doi.org/10.4161/onci.19549; PMID: 22737606
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; http://dx.doi.org/10.4161/onci.24238; PMID: 23762803
   PubMed Web of Science ®Google Scholar
• Stauss HJ, Morris EC. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther 2013; 20:1029 - 32; http://dx.doi.org/10.1038/gt.2013.34; PMID: 23804078
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509 - 18; http://dx.doi.org/10.1056/NEJMoa1215134; PMID: 23527958
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra38; http://dx.doi.org/10.1126/scitranslmed.3005930; PMID: 23515080
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur M, Lu W, Krause D, Van Etten R, Wels W, et al.. Retargeting NK-92 cells by means of CD19- and CD20-specific CARs compares favorably with antibody-dependent cellular cytotoxicity. OncoImmunology 2013;; Forthcoming
   PubMed Web of Science ®Google Scholar
• Terme M, Fridman WH, Tartour E. NK cells from pleural effusions are potent antitumor effector cells. Eur J Immunol 2013; 43:331 - 4; http://dx.doi.org/10.1002/eji.201243264; PMID: 23322344
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44 - 9; http://dx.doi.org/10.1126/science.1198687; PMID: 21212348
   PubMed Web of Science ®Google Scholar
• Tartour E, Mathiot C, Fridman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992; 46:473 - 84; http://dx.doi.org/10.1016/0753-3322(92)90005-R; PMID: 1306361
   PubMed Web of Science ®Google Scholar
• Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S, Mezzanzanica D. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother 2007; 30:684 - 93; http://dx.doi.org/10.1097/CJI.0b013e3180de5d90; PMID: 17893561
   PubMed Web of Science ®Google Scholar
• Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther 2012; 19:84 - 100; http://dx.doi.org/10.1038/cgt.2011.66; PMID: 21979579
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725 - 33; http://dx.doi.org/10.1056/NEJMoa1103849; PMID: 21830940
   PubMed Web of Science ®Google Scholar
• DeNucci CC, Mitchell JS, Shimizu Y. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. Crit Rev Immunol 2009; 29:87 - 109; http://dx.doi.org/10.1615/CritRevImmunol.v29.i2.10; PMID: 19496742
   PubMed Web of Science ®Google Scholar
• Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G, et al. Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5:172ra20; http://dx.doi.org/10.1126/scitranslmed.3004888; PMID: 23408053
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013; 73:3499 - 510; http://dx.doi.org/10.1158/0008-5472.CAN-13-0371; PMID: 23592754
   PubMed Web of Science ®Google Scholar
• Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K, Okamoto S, Mineno J, Kuzushima K, Shiku H, et al. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor. PLoS One 2013; 8:e56820; http://dx.doi.org/10.1371/journal.pone.0056820; PMID: 23441216
   PubMedGoogle Scholar
• Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17:1453 - 64; http://dx.doi.org/10.1038/mt.2009.83; PMID: 19384291
   PubMed Web of Science ®Google Scholar
• Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 2009; 21:525 - 30; http://dx.doi.org/10.1016/j.coi.2009.07.015; PMID: 19717293
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013; Forthcoming http://dx.doi.org/10.1182/blood-2013-08-519413; PMID: 24055823
   PubMed Web of Science ®Google Scholar
• Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10:625 - 32; http://dx.doi.org/10.1080/14653240802301872; PMID: 18836917
   PubMed Web of Science ®Google Scholar